Cannabidiol (CBD) Is a Novel Inhibitor for Exosome and Microvesicle (EMV) Release in Cancer.

Front Pharmacol · 2018 · PMC6099119 · PMID 30150937

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

a decreasing trendp ≤ 0.05actually significant

In PC3 cells, basal mitochondrial OCR showed a decreasing trend with increased dose of CBD, following 1 h CBD treatment at 1 μM (124.2 ± 9.6 pMoles/min; p ≤ 0.05) and 5 μM CBD (116.3 ± 13.1 pMoles/min), while not statistically significant compared to non-treated control (146.8 ± 12.9 pMoles/min) ( Figure 7D ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.